Drugs / rF-gp100P209
last change Dec 2008 re-read 2 minutes ago

rF-gp100P209

Vaccine

Developed for
melanoma
Investigated by
National Cancer Institute (NCI)

Trials 1 · a red edge is where a trial was stopped

200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00080353 Mar 2004 → Dec 2007 melanoma National Cancer Institute (NCI) Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as rF-gp100P209 “immunization with intravenous fowlpox virus rF-gp100P209NCT00080353
Modality Vaccine “an experimental vaccine called fowlpox gp100” NCT00080353
Route Intravenous intravenous fowlpox virus rF-gp100P209” NCT00080353